The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes
- 13 January 2023
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 9 (4) , 311-317
Abstract
In type 1 diabetes, average life expectancy is reduced by ˃10 years as compared with outside of diabetes. Residual cardiovascular risk defines high cardiovascular event rate despite modern, guideline-recommended standard of care of established risk factors like hypertension, dyslipidaemia, and glycaemic control, and it adds importantly to these lost years of life in type 1 diabetes due to atherosclerotic cardiovascular diseases like myocardial infarction and ischaemic stroke. With a growing understanding of inflammation as an important driver of atherosclerotic cardiovascular disease, residual inflammatory risk is a novel and common risk factor and a promising target for lowering residual cardiovascular risk in type 1 diabetes. Interestingly, the inexpensive anti-inflammatory agent colchicine reduced the risk of major adverse cardiovascular events by 25% in cardiovascular outcome trials in the secondary prevention of atherosclerotic cardiovascular disease. Here, we summarize the role of inflammation as a driver of atherosclerosis and review current evidence linking inflammation and atherosclerotic cardiovascular disease in type 1 diabetes. Also, we provide an overview of the evidence base for targeting residual inflammatory risk with colchicine for lowering residual cardiovascular risk in type 1 diabetes.Keywords
This publication has 71 references indexed in Scilit:
- C-Reactive Protein, Fibrinogen, and Cardiovascular Disease PredictionNew England Journal of Medicine, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Inflammatory Markers Are Increased in Youth with Type 1 Diabetes: The SEARCH Case-Control StudyThe Journal of Clinical Endocrinology & Metabolism, 2010
- Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuriaDiabetes & Vascular Disease Research, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Risk Factors Related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and Their Relationship With Nephropathy and Macrovascular ComplicationsDiabetes Care, 2008
- Connective Tissue Growth Factor and Susceptibility to Renal and Vascular Disease Risk in Type 1 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2008
- Soluble interleukin-2 receptor as a marker for progression of coronary artery calcification in type 1 diabetesThe International Journal of Biochemistry & Cell Biology, 2006
- CRP and IL‐6 concentrations are associated with poor glycemic control despite preserved β‐cell function during the first year after diagnosis of type 1 diabetesDiabetes/Metabolism Research and Reviews, 2004
- Colchicine inhibition of chemotaxisArthritis & Rheumatism, 1965